Spectra
Spectra- A novel diagnostic device to improve retinal imaging
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Spectra project word cloud
Explore the words cloud of the Spectra project. It provides you a very rough idea of what is the project "Spectra" about.
Project "Spectra" data sheet
The following table provides information about the project.
| Coordinator |
HEALTH INTELLIGENCE LTD
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Project website | https://health-intelligence.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-07-01 to 2015-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | HEALTH INTELLIGENCE LTD | UK (SANDBACH) | coordinator | 50˙000.00 |
Map
Project objective
Health Intelligence provide medical software as diagnostic medical devices. We have developed retinal (fundus) photograph analytical software - Spectra, complemented by the lower cost, standalone and portable Spectra Retineye. Spectra is one of only three software packages certified by the English National Diabetic Retinopathy (DR) Screening Programme. It has benefitted screening providers by seamless integration with patient records and ability to monitor over time. Providers reported improved throughput and attendance. Spectra highlights much more than just DR. In deployments to date, over 50% of urgent eye clinic referrals are for suspected non-diabetic retinopathies. Thus, Spectra detects reliable biomarkers for many conditions. The greatest causes of blindness (after cataracts) are glaucoma, age-related macular degeneration and DR. Spectra can detect early and treatable stages of these diseases, in particular low-pressure glaucoma missed by ocular pressure tests. New markets also exist for diabetic eye screening programmes (DESP) in countries lacking the resources of the UK NHS. Teleopthalmology (enabled by Spectra Retineye) could deliver these. Both Spectra and Spectra Retineye can deliver economic benefits: • Reducing need for expensive equipment and highly-qualified staff • Portability • Increased footfall in high-street optometrists from eye screening patients • Easier and lower cost of screening to patients • Reduced social security costs due to sight loss Spectra will deliver tremendous social benefits. Preventable, irreversible sight damage will become rarer, reducing sickness and caring burdens. Spectra Retineye, which is eminently adaptable to teleopthalmology will allow more delivery models. These will detect more problems earlier, including the 46% of diabetics who are unaware they have diabetes and thus risk severe sight loss and other health problems until they are identified.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPECTRA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SPECTRA" are provided by the European Opendata Portal: CORDIS opendata.